Integra LifeSciences Holdings Tops Q3 2026 Profit Forecast With $0.59 EPS

Integra (IART) reported Q3 EPS of $0.59, beating estimates by $0.03, but revenue of $411.2M missed expectations. Guidance for Q4 and FY 2026 was below consensus. The stock is down 40.17% over the last 3 months.

Integra LifeSciences (IART) reported Q3 2026 revenues of $411.2M, up 2.3%. GAAP EPS was $0.19, adjusted EPS $0.59. The company cited $7M revenue impact from flood damage and softer Tissue Reconstruction results. Full-year guidance remains unchanged at $1.634B-$1.654B revenue and $2.30-$2.40 adjusted EPS. Post-quarter, IART completed a $2.1B debt refinancing.

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.